The translated peptide HER2-103 promotes the proliferation and invasion of triple-negative breast cancer cells, and HER2-103 can also be used as a target molecule for the anti-HER2 targeted drug pertuzumab (Li et al., 2020). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.